Yoon H, et al. - Given that, cetuximab (Cx) plus irinotecan (Ir) has shown activity for second-line treatment of colorectal cancer, researchers assessed panitumumab (Pa, a fully humanized IgG2 monoclonal antibody against human EGFR) plus Ir as second-line therapy for advanced esophageal adenocarcinoma (EAC). Eligible patients were those with confirmed EAC, measurable disease, no prior treatment with Ir or Pa, performance status < 2, and normal organ function. No complete remissions were achieved. The median overall survival and median progression-free survival was 7.2 months and 2.9 months, respectively. Fatigue, diarrhea, anemia, leukopenia, and hypoalbuminemia were documented as the most common grade 1–2 adverse events. Grade 3–4 adverse events included hematologic, gastrointestinal, electrolyte, rash, fatigue, and weight loss. Overall, irinotecan and panitumumab showed no activity as second-line treatment for advanced EAC.